- Home
- ASC vs RIGL Comparison
ASC vs RIGL Comparison
Compare ASC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASC | RIGL |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.7M | 537.6M |
| IPO Year | 2013 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ASC | RIGL |
|---|---|---|
| Price | $11.82 | $49.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $13.67 | ★ $43.20 |
| AVG Volume (30 Days) | 607.3K | ★ 624.0K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.99% | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | 0.78 | ★ 6.20 |
| Revenue | ★ $309,326,000.00 | $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | N/A | $0.22 |
| P/E Ratio | $15.36 | ★ $7.90 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $8.32 | $14.63 |
| 52 Week High | $13.85 | $52.24 |
Technical Indicators
Market Signals| Indicator | ASC | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 64.29 |
| Support Level | $11.75 | $43.81 |
| Resistance Level | $12.41 | $52.24 |
| Average True Range (ATR) | 0.44 | 3.35 |
| MACD | -0.13 | -0.13 |
| Stochastic Oscillator | 3.04 | 75.13 |
Price Performance
Historical ComparisonAbout ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.